Validation of the Nccn-Ipi for Diffuse Large B-Cell Lymphoma (dlbcl) in A Nation-Wide Spanish Series of 1885 Patients. the Geltamo-Ipi Project

The development of the NCCN International Prognostic Index (NCCN-IPI) for patients with DLBCL treated in the rituximab era improves discrimination when compared to the original IPI model. The aim of the present study is to validate the results of the NCCN-IPI in a large independent series of patients in a different geographical area.